Boston Scientific BSX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net sales of reportable segments by Business | |||||
| Cardiovascular | $13.29B+22.6% | $10.84B+22.8% | $8.83B+13.0% | $7.81B+16.2% | |
| MedSurg | $6.84B+13.4% | $6.03B+11.0% | $5.43B+10.6% | $4.91B+12.0% | |
| Net Sales by Business | |||||
| Cardiovascular | $13.25B+23.2% | $10.76B+22.0% | $8.82B+12.6% | $7.83B+8.1% | |
| MedSurg | $6.82B+13.8% | $5.99B+10.5% | $5.42B+10.4% | $4.91B+6.0% | |
| Total assets of reportable segments by Business | |||||
| Cardiovascular | $30.71B— | —— | —— | —— | |
| MedSurg | $13.24B— | —— | —— | —— | |
| Other segment items by Business | |||||
| Cardiovascular | $25M+31.6% | $19M-17.4% | $23M+4.5% | $22M— | |
| MedSurg | $21M+50.0% | $14M-30.0% | $20M-13.0% | $23M— | |
| Operating Income (Loss), Adjusted by Business | |||||
| Cardiovascular | $4.32B+33.7% | $3.23B+37.2% | $2.36B+32.0% | $1.78B— | |
| MedSurg | $2.28B+9.0% | $2.09B+11.5% | $1.87B+25.7% | $1.49B— | |
| Selling, general and administrative expenses, percentage of net sale by Business | |||||
| Cardiovascular | 82.8%— | —— | 31.5%-0.5pp | 32%— | |
| Cost of products sold by Business | |||||
| Cardiovascular | $3.95B+15.7% | $3.41B+21.4% | $2.81B+6.5% | $2.64B— | |
| MedSurg | $1.92B+16.1% | $1.65B+12.2% | $1.47B+5.0% | $1.4B— | |
| Cost of products sold, percentage of net sale by Business | |||||
| Cardiovascular | 88.6%— | —— | 31.8%-2.5pp | 34.3%— | |
| MedSurg | 83.1%+1.3pp | 81.8%+54.7pp | 27.1%-1.8pp | 28.9%— | |
| Research and development expenses, percentage of net sale by Business | |||||
| Cardiovascular | 28.9%+1.9pp | 27%+17.3pp | 9.7%-0.5pp | 10.2%— | |
| MedSurg | 22.1%-0.8pp | 22.9%+15.0pp | 7.9%-1.0pp | 8.9%— | |
| Selling, general and administrative expenses by Business | |||||
| Cardiovascular | $3.69B+15.3% | $3.2B+15.1% | $2.78B+13.3% | $2.45B— | |
| MedSurg | $2.12B+16.7% | $1.82B+10.6% | $1.64B+8.7% | $1.51B— | |
| Impact of foreign currency fluctuations and purchase price and other adjustments by Business | |||||
| MedSurg | $53M— | —— | $0— | —— | |
| Research and development expenses by Business | |||||
| Cardiovascular | $1.31B+33.8% | $979M+14.0% | $859M+9.8% | $782M— | |
| MedSurg | $507M+9.7% | $462M+7.9% | $428M-0.9% | $432M— | |
| Goodwill by Business | |||||
| Cardiovascular | $41.49B+11.0% | $37.37B+3.4% | $36.12B+4.2% | $34.66B+39.6% | |
| MedSurg | $30.42B+29.4% | $23.52B+25.1% | $18.8B+10.9% | $16.95B+54.2% | |
| Depreciation by Business | |||||
| Cardiovascular | $355M+17.2% | $303M+15.2% | $263M+7.3% | $245M-6.1% | |
| MedSurg | $115M+5.5% | $109M+5.8% | $103M+17.0% | $88M-3.3% | |
| Goodwill acquired by Business | |||||
| Cardiovascular | $890M+44.7% | $615M— | —— | $1.03B-32.2% | |
| MedSurg | $173M— | —— | $1.11B— | $0-100% | |
| Net Sales by Product | |||||
| Cardiac Rhythm Management | $2.33B+2.4% | $2.28B+2.7% | $2.22B+5.7% | $2.1B+4.0% | |
| Electrophysiology | $3.33B+74.6% | $1.9B+138% | $800M+36.8% | $585M+60.7% | |
| Endoscopy | $2.92B+8.5% | $2.69B+8.2% | $2.48B+11.7% | $2.22B+3.8% | |
| Interventional Cardiology & Vascular Therapies | $4.64B+10.5% | $4.2B+10.8% | $3.79B— | —— | |
| Neuromodulation | $1.2B+8.6% | $1.11B+13.3% | $975M+6.3% | $917M+0.9% | |
| Urology | $2.71B+23.1% | $2.2B+12.0% | $1.96B+10.8% | $1.77B+12.0% | |
| Watchman | $1.96B+29.2% | $1.52B+18.9% | $1.28B+25.1% | $1.02B+22.9% | |
| Net Sales by Geography | |||||
| Asia-Pacific | $3.08B+14.7% | $2.69B+11.8% | $2.4B+13.5% | $2.12B+2.3% | |
| Europe, Middle East and Africa | $3.45B+6.9% | $3.23B+13.1% | $2.86B+13.0% | $2.53B+0.3% | |
| Latin America and Canada | $678M+8.5% | $625M+11.6% | $560M+19.7% | $468M+21.2% | |
| U.S. | $12.86B+26.0% | $10.21B+21.2% | $8.43B+10.4% | $7.63B+10.4% | |
| Long-Lived Assets by Geography | |||||
| Costa Rica | $2.36B— | —— | —— | —— | |
| Ireland | $2.81B— | —— | —— | —— | |
| U.S. | $6.78B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
